Business Segments UCB

Stocks

Market Closed - Euronext Bruxelles Other stock markets 11:55:00 2026-07-20 EDT			5-day change	1st Jan Change
238.00 ^EUR	-0.54%		+1.02%	-0.25%

07-14	Where would AI lead Pharma in the long run?
07-13	Antengene Receives $60 Million Milestone in UCB Licensing Deal	MT

Breakdown by Business Segment (EUR)

Fiscal Period: December	2021	2022	2023	2024	2025
Pharmaceutical Products
Biopharmaceuticals	5.78B	5.45B	5.18B	6.15B	7.74B
Total Assets	14.21B	15.87B	15.54B	17.35B	18.16B
Interest Expense	-45M	-72M	-144M	-161M	-128M
Income Tax Expense	170M	91M	98M	98M	264M
CAPEX	-493M	-371M	-238M	-234M	-281M
EBT	1.23B	511M	441M	1.16B	1.82B
Gross Profit	4.34B	3.84B	3.54B	4.4B	5.75B
D&A	323M	587M	691M	641M	627M
Operating Income	1.28B	585M	604M	1.32B	1.95B
Net Income	1.06B	418M	343M	1.06B	1.56B

Geographical breakdown of sales (EUR)

Fiscal Period: December	2021	2022	2023	2024	2025
United States	2.89B	2.9B	2.45B	3.04B	4.61B
Total Assets	131M	151M	138M	169M	133M
International Markets	429M	507M	554M	575M	592M
Total Assets	23M	21M	18M	25M	25M
Europe Other (Excluding Belgium)	331M	348M	365M	401M	441M
Germany	335M	330M	310M	364M	425M
Total Assets	21M	20M	23M	24M	23M
Japan	561M	324M	269M	257M	315M
Total Assets	25M	19M	17M	17M	18M
Spain	202M	213M	224M	244M	271M
France (Including French Territories)	172M	169M	162M	177M	195M
Italy	159M	154M	143M	171M	183M
U.K. and Ireland	150M	151M	133M	164M	165M
Total Assets	184M	181M	215M	269M	330M
Total Assets	259M	251M	240M	217M	236M
Unallocated	57M	-167M	50M	19M	94M
Belgium	47M	49M	52M	61M	77M
Total Assets	609M	771M	924M	1.03B	1.15B
China	140M	159M	151M	143M	20M
Total Assets	23M	20M	20M	1M	3M
Brazil	-	-	-	-	-
Total Assets	-	-	-	-	-